None VolunteerPhase 2NCT07878130
An Investigation of Mechanisms That Underly Paranoia in Behaviour and Brain That Can Inform Clinical Diagnoses That Include Paranoid Symptoms.
A Phase 2 study testing Low-dose THC administration via IV, High-Dose THC administration via IV and Saline administration via IV in people with None Volunteer, run by King's College London at 1 site in United Kingdom.
Trial summary
The study team is studying how delta-9-tetrahydrocannabinol (THC) - the component of cannabis that is responsible for "getting people feeling high" - influences how people think about the behaviour of others and a variety of other experiences. The study team is investigating these processes in healthy adults. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- None Volunteer
- What is being tested?
- Low-dose THC administration via IV, High-Dose THC administration via IV and Saline administration via IV
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Nov 2026to 30 Sep 2028
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Have used cannabis at least once in the past
- Willing and able to provide written informed consent
- Willing to provide blood samples for screening purposes
- Agrees to use highly effective methods of contraception for the duration of the study and for 3 months after the final study visit (see Contraception below)
- Be able to understand the information sheet
Who cannot join
- Having a past or present major mental illness
- Having a past or present major physical illness (e.g. respiratory or heart condition)
- Not having a normal ECG reading at screening visit
- Having screening blood tests outside normal ranges, determined to be clinically significant
- Having a past or present substance use disorder
- Having ever been treated with an anti-psychotic or anti-depressant medication
Show all 20Show fewer
- Having a first degree relative (parent or sibling) with psychotic illness
- Currently taking psychotropic medication
- Having a positive urine drug screen (any drug) at any of the study visits (baseline and experimental sessions)
- Having self-reported use of alcohol within 24h of an experimental visit or a positive alcohol breath test
- Being pregnant or planning pregnancy or lactating in women
- Discovery of significant abnormality during physical examination at screening visit
- Is using cannabis (defined as days in which cannabis is used recreationally) more often than once per week on average over the last 12 months.
- Smoking more than 4 cigarettes or vapes per week.
- Drinking more than 4 units (100ml) of coffee per day.
- Any past use of synthetic cannabinoids
- Having a score of 5 or more on the Fagerstrom Nicotine Dependence Questionnaire
- Having a BMI classified as obese or underweight (below 18 or over 30)
- Having participated in a drug study within the last 30 days
- Having a known sensitivity or allergy towards cannabis or Lorazepam
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site
King's College London
London, SE6 8AF
Mitul Mehta, +44 20 3228 2121, mitul.mehta@kcl.ac.uk
About this study
Official title: Bridging the Neurocomputational Explanations of Paranoia: From Cognition to Clinic
The study team is studying how delta-9-tetrahydrocannabinol (THC) - the component of cannabis that is responsible for "getting people feeling high" - influences how people think about the behaviour of others and a variety of other experiences. The study team is investigating these processes in healthy adults. The study team uses computer-based tasks and questionnaires to understand how people make conclusions about other people's intentions under different circumstances.
In this study, the study team uses a placebo-controlled within-participant study design with three different conditions: (i) 1mg/ml THC administration, (ii) 2mg/ml THC administration, and (iii) placebo (Saline) administration, all via an intravenous IV. The study is within-participants, meaning that every participant will experience all three conditions. The study is double blind, meaning that neither the researcher nor the participant will know what condition they will be in on a given study visit. The sequence of conditions is balanced across participants.
- Conditions
- None Volunteer
- Being tested
- Low-dose THC administration via IV, High-Dose THC administration via IV, Saline administration via IV
- Keywords
- THC, paranoia, cannabis, social inference, social processing, computational psychiatry, computational modeling
- Medical subject headings
- Paranoid Disorders, Marijuana Abuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low-dose THC administration via IVDrug
The study drug for this study is synthetically derived delta-9-tetrahydrocannabinol (THC, International Non-proprietary Name: Dronabinol). THC Active Pharmaceutical Ingredient (API) is provided by Purisys LLC (CDMO), Georgia, USA; and formulated into a solution for intravenous injection by Hybrid Pharma, Florida USA. As detailed in D'Souza et al., 2004, THC is dissolved in 95% ethanol (Agurell et al. 1986) to yield a concentration of 12 mg/ml stock solution which was then passed through a polymer filter, subjected to sterility and pyrogenicity testing, and assayed by gas chromatography mass spectrometry to confirm its concentration and stored at room temperature for future use. Hybrid Pharma will provide 5 ml vials of active drug and matched placebo (ethanol solution without THC). In the high-dose condition, 1mg/ml will be administered over 20min via IV.
High-Dose THC administration via IVDrug
The study drug for this study is synthetically derived delta-9-tetrahydrocannabinol (THC, International Non-proprietary Name: Dronabinol). THC Active Pharmaceutical Ingredient (API) is provided by Purisys LLC (CDMO), Georgia, USA; and formulated into a solution for intravenous injection by Hybrid Pharma, Florida USA. As detailed in D'Souza et al., 2004, THC is dissolved in 95% ethanol (Agurell et al. 1986) to yield a concentration of 12 mg/ml stock solution which was then passed through a polymer filter, subjected to sterility and pyrogenicity testing, and assayed by gas chromatography mass spectrometry to confirm its concentration and stored at room temperature for future use. Hybrid Pharma will provide 5 ml vials of active drug and matched placebo (ethanol solution without THC). In the high-dose condition, 2mg/ml will be administered over 20min via IV.
Saline administration via IVDrug
Saline will be administered intravenously rather than THC
| Study group | Role | What they receive |
|---|---|---|
| placebo | Placebo comparator | Application of saline solution instead of THC solution intravenously over 20min Receives: Drug: Saline administration via IV |
| Low Dose THC | Experimental | Application of 1mg THC /ml solution intravenously over 20min Receives: Drug: Low-dose THC administration via IV |
| High Dose THC | Experimental | Application of 2mg THC /ml solution intravenously over 20min Receives: Drug: High-Dose THC administration via IV |
What is being measured
The primary outcome is the main question the study is designed to answer.
Harmful intent attribution
Participants will play a task (Sharing Game), where they have make intent attributions to an agent they are interacting with. The attribution will be made on a visual analogue scale ranging from 1 to 100 with higher numbers representing more harmful intent attribution. The outcome variable will be estimated using a computational model that takes more aspects of the task into account
Measured: Study day 1 to 4, max. within three months, i.e. baseline visit, experimental visit 1 - after intervention and task, experimental visit 2 - after intervention and task, experimental visit 3 - after intervention and task
Secondary outcomes (9)
Social behaviours and decision making under uncertainty as measured by the Sharing Game and similar games.
participants are engaging in a set of tasks that measure inference and decision making. Outcome measures are estimated using a computational model that takes other aspects of the task and decision making into account as is custom in computational modeling of behaviour in cognitive psychology and computational psychiatry.
Measured: Study day 1 to 4, max. within three months, i.e. baseline visit, experimental visit 1 - after intervention and task, experimental visit 2 - after intervention and task, experimental visit 3 - after intervention and task
Immediate recall on the HVLT-R
Hopkins verbal learning task - Revised (HVLT-R) is a part of the MATRICS Consensus Cognitive Battery (PAR, Inc FL 33549). The first phase of the test is an immediate recall phase where participants are read a list of 12 words across three trials (nouns from three taxonomic categories) and participants have to recall the words immediately after. There are 5 validated versions of the HVLT-R and the order of test versions will be randomised for each participant to prevent potential order effects. The more words recalled the higher the score.
Measured: Study day 1 to 4, max. within three months, i.e. baseline visit, experimental visit 1 - before intervention, experimental visit 2 - before intervention and task, experimental visit 3 - before intervention and task
Delayed recall on the HVLT-R
Hopkins verbal learning task - Revised (HVLT-R) is a part of the MATRICS Consensus Cognitive Battery (PAR, Inc FL 33549). It consists of an immediate recall phase where participants are read a list of 12 words across three trials (nouns from three taxonomic categories). This is followed by a delayed free recall phase between 20-25 minutes after completion of the immediate recall phase where then participant is asked to recall as many of the words from the list as they can remember. Repetitions and intrusions (words recalled not part of the original list) will also be recorded for each trial. There are 5 validated versions of the HVLT-R and the order of test versions will be randomised for each participant to prevent potential order effects. Delayed recall is measured by how many words are remembered after the delayed free recall phase. More words remembered result in higher scores.
Measured: Study day 1 to 4, max. within three months, i.e. baseline visit, experimental visit 1 - before intervention, experimental visit 2 - before intervention and task, experimental visit 3 - before intervention and task
Working memory performance (Digit Span)
Forward and reverse digit span refers to the longest list of numbers the participant can correctly recall, both in forward and backward order. The task starts at the length of four digits (three for backward) and is increased by one digit for each successful trial. The task is ended when the participant fails to give the correct order after two consecutive attempts. The further participants get in the test the better working memory performance.
Measured: Study day 1, i.e. Baseline visit
Paranoia score (SPSS)
State social paranoia scale (SSPS) is a 10-item instrument which measures persecutory thoughts. The persecutory items (e.g. 'someone had bad intentions towards me') are presented among 10 neutral items and scored on a 5-point scale (do not agree - totally agree).
Measured: Study day 1 to 4, max. within three months, i.e. Baseline visit, Experimental visit 1 - before intervention, Experimental visit 2 - before intervention, Experimental visit 3 - before intervention
Positive psychotic symptoms (PANSS-P)
Positive and negative syndrome scale - positive subscale (PANSS-P) is the most common scale to measure psychotic symptoms and commonly used in schizophrenia research. The PANSS is an investigator rated scale and is scored following a semi-structured interview. In this study only the positive subscale will be used, which include the following symptoms: delusions, conceptual disorganisation, hallucinations, hyperactivity, grandiosity, suspiciousness and hostility. The symptoms are scored on a 7-point scale from absent-severe.
Measured: Study day 1 to 4, max. within three months, i.e. Baseline visit, Experimental visit 1 - before intervention, Experimental visit 2 - before intervention, Experimental visit 3 - before intervention
Mood States
Visual analogue scales (VAS) consist of words which describe feeling states and a 100mm horizontal line on which the participant indicates with a vertical line how much of that feeling they have experienced in the moment. The scale ranges from "Not at all" (0mm) to "As much as could possibly be" (100mm).
Measured: Study day 2 to 4, max. within three months, i.e. Experimental visit 1 - before and after intervention, Experimental visit 2 - before and after intervention, Experimental visit 3 - before and after intervention
Paranoia
Visual analogue scales (VAS) consist of words which describe feeling states and a 100mm horizontal line on which the participant indicates with a vertical line how much of that feeling they have experienced in the moment. The scale ranges from "Not at all" (0mm) to "As much as could possibly be" (100mm). Six paranoia VAS from Freeman et al., (2015) will also be included: "Right now I feel suspicious of other people," "Right now I feel that people want to harm me," "Right now I feel like people want to upset me," "Right now I feel like people are against me," "Right now I am thinking that others are trying to persecute me," and "Right now I feel like people are being hostile towards me".
Measured: Study day 2 to 4, max. within three months, i.e. Experimental visit 1 - before and after intervention, Experimental visit 2 - before and after intervention, Experimental visit 3 - before and after intervention
Heartrate related markers
Heart beat will be measured using a standard pulse-oximeter. Systolic blood pressure peaks will be used as a proxy for the R-peak and Inter-beat-intervals will be calculated based on consecutive systolic blood pressure peaks. Heart rate variability will be operationalized as RMSSD based on these inter-beat-intervals.
Measured: Study day 1 to 4, max. within three months, i.e. Baseline visit - before and during task, Experimental visit 1 - before and during task, Experimental visit 2 - before and during task, Experimental visit 3 - before and during task
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2026
- Study start1 Nov 2026 (estimated)
- Primary completion30 Sep 2028 (estimated)
- Study completion30 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for None VolunteerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- within-participants, placebo controlled. Sequence with which participants receive intervention (placebo, 1mg, and 2mg) is randomized across participants
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King's College London
- Sponsor type
- University, hospital or other
- Collaborators
- South London and Maudsley NHS Foundation Trust
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07878130
- Sponsor's protocol ID
- NEPTUNE
- Other IDs
- 317835/Z/24/Z
- Status last verified
- Sep 2026
- First submitted
- 18 Sep 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: In the informed consent, participants consent for their fully anonymized data to be shared with other researchers and collaborators. Outcome measures as specified in "Outcome measures" section.